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ABSTRACT 
Background: Implementation of new practice guidelines for stroke prevention has decreased the number of patients experiencing 
recurrent stroke. Clinical trials show antihypertensives, high-intensity statins, and antithrombotics to be beneficial after stroke. 
Objective: The objective of this study was to determine if recurrent stroke patients were discharged on guideline-based medications 
for secondary stroke prevention, and to identify potential errors in appropriate prescribing of medications. Methods:  A retrospective 
chart review was conducted at a community hospital and included patients 19 years and older diagnosed with their second, third, or 
fourth stroke (transient ischemic attack or cerebrovascular accident). Descriptive statistics were used to describe collected information. 
Collected data included relevant patient demographics, diagnosis, past medical history, medications, and readmission rates. The 
primary objective was the percentage of patients appropriately discharged on guideline-based secondary stroke prevention 
medications. Appropriate treatment was based upon the 2010 and 2014 American Heart Association/American Stroke Association 
Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. Results:  A total of 124 charts were 
reviewed, 106 charts met the inclusion criteria. Guideline-based and appropriate medication-use was initiated in 9% and 4% of patients 
with noncardioembolic and cardioembolic stroke, respectively. Therapy deemed not guideline-based, but appropriate was initiated in 
20% and 9% of patients with noncardioembolic and cardioembolic stroke, respectively. Errors in appropriate prescribing of secondary 
prevention medications were related to statins and antihypertensives. Conclusion: Better adherence to preventative recurrent stroke 
measures is needed at the time of patient discharge.  
 
Keywords: ischemic stroke, recurrent stroke, recurrent stroke prevention, secondary stroke prevention 
 
 
BACKGROUND 
Stroke is the second leading cause of death in the world, the 
fourth leading cause of death in the United States, and the 
leading cause of long-term disability.1 The American Heart 
Association (AHA) reported in 2015 that higher rates of stroke 
exist among older adults, people with lower education, African-
Americans, and people who live in the southeastern United 
States.1 Stroke mortality is 20% higher in the stroke belt, 
including Alabama, than in the rest of the population, and this 
mortality rate doubles from 22% in primary stroke to 44% in 
recurrent stroke.1,2 The annual rate of recurrent stroke is 
projected to decline from 5% in the 2000s to a little over 2% in 
the 2010s.1 This decline may be attributed to the improvement 
in treatment options for secondary stroke prevention.3  
 
Stroke recurrence not only increases the risk of death, but also 
increases disability and dependence on health services.4 Of the 
80% of stroke survivors that return post-stroke discharge, 
about half require permanent or temporary help from other  
people.5 Close family members, e.g. spouses or children, are  
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usually the caregivers for patients, and one-half of these family 
caregivers experience a high level of burden one year after their 
loved one’s stroke.5 A projected 3.4 million additional people 
will experience a new or recurrent stroke from 2012 to 2030, 
and the total direct medical stroke-related costs are projected 
to triple from $72 billion to $184 billion.1,6 With the increased 
emotional and economic burden of stroke in the United States 
and internationally, aggressive treatment of stroke risk factors 
is imperative.  
 
Medication Management 
Medications that significantly lower ischemic stroke risk include 
antihypertensives, HMG-CoA Reductase inhibitors (statins), 
antiplatelets, and anticoagulants.3 According to the 2010 and 
2014 American Heart Association/American Stroke Association 
(AHA/ASA) secondary stroke prevention guidelines, 
management of hypertension and dyslipidemia, as well as use 
of antithrombotic therapy, are beneficial for secondary stroke 
prevention. Initiation or resumption of antihypertensives is 
recommended following stroke to achieve blood pressure 
levels of <140 mmHg systolic and <90 mmHg diastolic.7,8 
Lowering blood pressure is associated with significant 
reductions in stroke, myocardial infarctions, and total vascular 
events.9 Recommendations for antihypertensive therapy 
regimens are limited, but available data suggest use of diuretics 
with or without angiotensin-converting enzyme inhibitors (ACE 
inhibitors).7,8 The treatment of dyslipidemia includes statins, 
which prevent secondary stroke by decreasing the progression 
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and promoting the regression of carotid artery plaques.10 The 
recommendation for dyslipidemia therapy in secondary stroke 
prevention is use of high-intensity statins (HI statins) to 
decrease low-density lipoprotein cholesterol (LDL-C) blood 
levels by about 50% with a goal LDL<70 mg/dL.11  
 
Antithrombotic therapy is indicated in all ischemic strokes, with 
the selection of therapy dependent on the type of stroke 
experienced. Two of the types of stroke that may occur are 
noncardioembolic and cardioembolic.12,13 Antiplatelet therapy 
is indicated for all ischemic strokes, but if the stroke is 
cardioembolic in nature, oral anticoagulation therapy may be 
indicated instead.7,8 The goal of antithrombotic therapy is to 
prevent the formation of future clots, and as a result, future 
strokes. Other modifiable risk factors for secondary stroke 
prevention such as smoking cessation, diabetes management, 
and weight loss, are addressed in the guidelines but were not 
addressed in this study. 
 
OBJECTIVE 
The purpose of this study was to determine if recurrent stroke 
patients were discharged on guideline-based medications for 
secondary stroke prevention at a community hospital, and to 
identify errors in prescribing of these preventative medications. 
 
METHODS 
Study Design 
A retrospective chart review was conducted at a small 
community hospital outside of Birmingham, Alabama. Approval 
for this retrospective chart review was obtained from the 
Samford University Institutional Review and the Baptist Health 
System Human Research Review Boards (IRB # S-1076). A 
waiver of informed consent was obtained due to the scope and 
retrospective nature of the study. The study involved reviewing 
charts of patients at least nineteen years old who were 
diagnosed with their second, third, or fourth stroke (transient 
ischemic attack or cerebrovascular accident) between May 30, 
2010 and May 30, 2015. Patients who did not have complete 
documentation, expired prior to discharge, or were discharged 
on comfort measures only were excluded from the study. The 
following data was collected:  age, gender, weight, race, 
number of stroke, medications on admission and discharge, 
relevant laboratory values and allergies, location and length of 
stay in hospital, and if readmitted for stroke within thirty days 
after discharge.  
 
The primary objective measured was the percentage of patients 
discharged on guideline-based stroke prevention medications. 
Secondary objectives measured included patients discharged 
on medications that were appropriate, but not guideline-based, 
and percentages of each class of secondary stroke prevention 
medications patients were discharged on. Once data was 
collected, descriptive statistics including averages and 
percentages were used to analyze the data. 
 
Defining the Criteria 
Data collected on patients’ discharge medications was 
compared to the recommended medications for each 
modifiable risk factor and type of stroke. Appropriate guideline-
based treatment was based upon the 2010 and 2014 AHA/ASA 
Guidelines for the Prevention of Stroke in Patients With Stroke 
and Transient Ischemic Attack. The recording of medications on 
admission and discharge was focused on the following classes 
of medications:  diuretics (loop, thiazide, thiazide-like, or 
potassium-sparing classes), ACE inhibitors (any agent in class), 
statins (high-intensity), antiplatelets (aspirin, aspirin and 
extended-release dipyridamole, clopidogrel, or ticlodipine), 
and anticoagulants (warfarin, rivaroxaban, dabigatran, or 
apixaban).  
 
Additional criteria for dyslipidemia and antithrombotic 
treatment were considered. ASA/AHA guidelines for the 
treatment of dyslipidemia in secondary stroke prevention 
recommend use of high-intensity statins, but the guidelines 
defer to the 2013 American College of Cardiology/American 
Heart Association (ACC/AHA) Blood Cholesterol Guidelines for 
patients with ischemic stroke and other comorbid clinical 
atherosclerotic cardiovascular disease (ASCVD).7,8,14 The 
ACC/AHA guidelines further define criteria for statin therapy in 
secondary stroke prevention. For adults ≤75 years old with 
clinical ASCVD not currently on statin therapy or are on a low- 
or moderate-intensity statin, a high-intensity statin should be 
started.14 For patients where a high-intensity statin is 
intolerable or contraindicated, or for patients >75 years old, a 
moderate-intensity statin may be used.14 Recommendations for 
antithrombotic treatment are antiplatelet therapy unless 
anticoagulation is indicated.7,8 Combination treatment with an 
antiplatelet and an anticoagulant may be indicated for some 
patients, e.g. those with clinically apparent coronary artery 
disease, especially after a myocardial infarction or stent 
placement.8 
 
To determine if a patient was on guideline-based and 
appropriate medications, they had to be on all of the 
recommended medications, depending on the type of ischemic 
stroke. For example, a patient who experienced a 
noncardioembolic stroke would need to be on a diuretic with or 
without an ACE inhibitor, a high-intensity statin, and an 
antiplatelet. For a patient who experienced a cardioembolic 
stroke, he or she had to be on a diuretic with or without an ACE 
inhibitor, a high-intensity statin, an oral anticoagulant with or 
without an antiplatelet depending on other comorbid 
conditions. For a patient with allergies or contraindications to 
the recommended medications (e.g. angioedema with an ACE 
inhibitor, impaired renal function as a result of or preventing 
use of a diuretic, or myopathy from a statin), the investigators’ 
clinical judgement was used to determine if the regimen he or 
she was discharged on was appropriate, even if not guideline-
based.  If a patient was not on the guideline-based medications, 
and there were no documented contraindications, he or she 
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was considered to be discharged on a regimen that was not 
guideline-based. 
 
RESULTS 
Data collection and analysis was conducted from the electronic 
health record at a small community hospital. Analysis was 
conducted using descriptive statistics. Nominal data, including 
the number of patients who were discharged on appropriate 
preventative medications, were analyzed using proportions.  
 
A total of 124 patient charts were reviewed, and 105 patients 
were included in the analysis. The excluded patients did not 
meet inclusion criteria and were therefore removed from 
analysis. Of the 105 patients, 82 experienced a 
noncardioembolic stroke and 23 experienced a cardioembolic 
stroke.  The majority of patients were admitted with their 
second stroke (84%).  The patients in the study were 68 years 
old on average, 54% male, and 83% white (Table 1).  
 
Guideline-based and appropriate medication use was initiated 
at discharge in 8% and 4% of patients with noncardioembolic 
and cardioembolic stroke, respectively. Therapy deemed not 
guideline-based, but appropriate was initiated in 20% and 9% 
of patients with noncardioembolic and cardioembolic stroke, 
respectively (Table 2). At discharge, 70 to 90% of patients who 
were admitted with their second, third, or fourth stroke were 
on inappropriate secondary prevention treatment. Errors in 
prescribing at discharge for noncardioembolic and 
cardioembolic strokes were largely related to antihypertensive 
and high-intensity statin use. Evaluation of antihypertensive 
use reveals that 15% of patients with noncardioembolic stroke 
and 26% of patients with cardioembolic stroke were discharged 
on a diuretic plus an ACE inhibitor; 13% and 4% were discharged 
on a diuretic only. Use of an ACE inhibitor without a diuretic was 
used in 52% and 65% of patients with noncardioembolic and 
cardioembolic strokes, respectively. Of note, 16 patients were 
discharged on an angiotensin II receptor blocker (ARB) in place 
of an ACE inhibitor. The use of high-intensity statins was 26% in 
patients with noncardioembolic stroke and 17% in patients with 
cardioembolic stroke. Appropriate use of moderate-intensity 
statins in place of high-intensity statins was initiated in 13 
patients overall.  
 
Antithrombotic therapy was prescribed the the vast majority of 
patients with 95% of patients receiving an antiplatelet if they 
had a noncardioembolic stroke, and 96% of patients receving 
an oral anticoagulant  if they had a cardioembolic stroke.  Of 
note, in patients with a cardioembolic stroke, 18 were 
prescribed an oral anticoagulant plus an antiplatelet. Of those 
18 patients, only 10 had documented indications of atrial 
fibrillation and coronary artery disease. All percentages of 
medication class-specific use are listed in Tables 5 and 6 and 
Figures 1 and 2.  
 
 
DISCUSSION 
The findings in this study reveal that a sample of patients in this 
community hospital were not discharged on guideline-based or 
appropriate medications for secondary stroke prevention. The 
majority of deviations in prescribing from guidelines are related 
to hypertension and dyslipidemia management. While some 
clinicians may argue that guidelines serve to provide guidance 
to practitioners and are not a set of rules to adhere to, there is 
ample evidence to promote current guidelines for management 
post-stroke as “best practices”. Evidence to support guideline 
recommendations for post-stroke pharmacotherapy 
management is discussed in the sections below.  
 
Dyslipidemia and Hypertension Management 
Before and during the development of the AHA/ASA stroke 
guidelines, new studies were conducted investigating effective 
management of dyslipidemia and hypertension after stroke. 
The landmark study illustrating benefit of high intensity statins 
was the SPARCL trial, which evaluated the use of atorvastatin 
80 mg versus placebo.15 Atorvastatin 80 mg reduced the overall 
risk of stroke despite an increased incidence of hemorrhagic 
stroke.15 The most common adverse effect reported in the 
study was elevated liver enzymes.15 Even with the potential for 
hepatic injury, high-intensity statins are recommended as 
tolerated, with a moderate-intensity statin used as a secondary 
option.7,8,14 Furthermore, studies evaluating the use of 
moderate-intensity statins in secondary stroke prevention 
showed that individuals >75 years experienced a reduction in 
ASCVD events, compared with control. A moderate-intensity 
statin should be considered for individuals >75 years with 
clinical ASCVD, unless they are currently tolerating a high-
intensity statin.14 In this study, thirteen patients met the criteria 
for initial use of a moderate-intensity statin, but many patients 
were either continued or started on a moderate-intensity 
statin. Arnan et al published a study that addressed secondary 
stroke prevention in the elderly.16 The investigators pointed out 
that stroke mortality increases with age, and the majority of 
strokes occur in those over 65 years of age. This finding 
correlates to those found in this study, as the average age of 
patients experiencing a recurrent stroke was 68 years old. They 
acknowledged the concern for adverse effects in the elderly 
and agreed with the recommendation of the 2013 ACC/AHA 
cholesterol guidelines. Overall, with the increased incidence 
and risk of poor outcomes, it is even more important to have 
close follow-up and management of elderly patients. 
 
Studies evaluating hypertension management include the 
HOPE trial, the PROGRESS trial, the MOSES trial, and the 
PRoFESS trial.17-22  The HOPE trial evaluated the use of ramipril 
versus placebo and revealed that despite a modest reduction in 
blood pressure, ramipril reduced the incidence of stroke and 
other vascular events over the four and a half years of the 
study.18,19 The PROGRESS trial evaluated the use of perindopril 
versus placebo; indapamide could be added to the treatment 
regimen at physicians’ discretion as well.20 Over the four year 
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study, the combination of an ACE inhibitor and diuretic 
produced a greater reduction in blood pressure, and a larger 
risk reduction versus the ACE inhibitor alone.  
 
The MOSES trial sought to evaluate the benefit of eprosartan 
versus nitrendipine.21 Over the two and a half year follow-up, 
there was a comparable decrease in blood pressure between 
the two groups, but the combined primary end point of 
cardiovascular and cerebrovascular events was significantly 
lower in the eprosartan group. In contrast, a few years later, the 
PRoFESS trial evaluated the use of telmisartan (ARB) versus 
placebo in a larger sample of patients.22 After a two and half 
year follow-up, telmisartan did not significantly lower the rate 
of recurrent stroke. There is a need for more studies 
investigating the different therapy options for hypertension 
management post-stroke. One limitation to most studies is that 
African Americans and other racial-ethnic minorities are under-
represented in the trials, even though these minorities are 
associated with a higher risk of stroke and other vascular 
diseases.2 Therefore, it would be beneficial for future studies to 
investigate not only alternative regimens, but specific regimens 
for other patient populations.  
 
Boan et al reported that up to 50% of strokes might be 
attributable to exposure to high blood pressure, and initiation 
of antihypertensives while in the hospital potentially improves 
both medication adherence and risk of recurrent vascular 
events. 17 In the study, investigators analyzed the use of 
antihypertensives one-year post-stroke hospitalization. A total 
of 270 patients were included. About 80% of the patients were 
discharged on antihypertensive therapy. Of those not 
discharged on antihypertensives, 26% were started on therapy 
prior to follow-up, whereas 74% were never started on therapy 
after hospital discharge. The study further subdivided the use 
of medications by class. About 30% of patients were discharged 
on a diuretic in the study, which correlated to the findings of 
this study. In another study conducted by the same 
investigators, the investigators reported that blood pressure 
remains poorly controlled throughout long-term follow up after 
stroke.2  The study emphasized the overwhelming gray area 
surrounding lowering blood pressure for recurrent stroke 
prevention; when and how to lower blood pressure post-
stroke, and if different regimens are beneficial in different 
groups of patients.2  
 
The NEMESIS study in Australia examined blood pressure 
control at five years post-stroke.23 About 450 patients were 
evaluated in the study, but only 300 of them had complete data 
(blood pressure measurement, medication records, and 
survey). Results showed that 82% of the patients were 
diagnosed with hypertension; 52% were controlled (90% on 
therapy), and 30% were uncontrolled (67% on therapy). Rashid 
et al conducted a systematic review of seven randomized 
clinical trials that evaluated lowering blood pressure for 
secondary stroke prevention.9 The investigators reported that 
trials evaluating hypertension management recruited patients 
regardless of what their blood pressure was, and lowering the 
blood pressure resulted in decreased vascular events, including 
recurrent stroke. Blood pressure management compared to 
dyslipidemia management is a treat-to-goal recommendation 
versus a fixed-dose recommendation with high-intensity 
statins. Close management and follow-up with blood pressure 
control post-stroke is crucial. 
 
Standardized Discharge Orders 
Multiple studies have evaluated the use of standardized 
discharge orders as well as integrated care plans post-stroke. 
Currently there is insufficient evidence to support routine 
implementation of standardized discharge orders. Johnston et 
al. evaluated the use of standardized discharge orders at the 
hospital level for adherence to preventative measures six 
months post-discharge from an ischemic stroke.24 The study 
evaluated the adherence to normalization of blood pressure, 
treatment with a statin, and treatment with anticoagulation 
among patients with atrial fibrillation; outcomes measured 
using documentation of prescription refills and achieving 
normal blood pressure after six months. The study did not 
evaluate the use of antiplatelets among patients because the 
investigators were unable to follow-up with prescription refills, 
as many patients received their antiplatelet over-the-counter. 
An estimated 3000 patients were included in this study. Overall, 
the implementation of standardized discharge orders resulted 
in greater adherence to the study’s primary outcome measure, 
but the results were not statistically significant. The 
investigators concluded that even though there was no 
statistical significance in the study, standardized discharge 
orders were a focused, inexpensive intervention. A limitation of 
this study would be the lack of antiplatelet evaluation. Even 
though many patients receive their antiplatelet over-the-
counter, i.e. aspirin in various doses, other antiplatelets, 
clopidogrel and aspirin-dipyridamole, are utilized post-stroke 
and are prescription only medications. 
 
Another study by Wolfe et al evaluated the benefit of extensive 
patient education and team management of medications and 
risk factors.4 The study also found no statistical significance; 
however, during the study, the United Kingdom Department of 
Health introduced quality and outcome measure strategies. 
Investigators believe these skewed the results, as the health 
care professionals were impacted by this change, and this was 
not accounted for in the original design of the study. A 
multicenter trial in Australia developed a standardized 
integrated care (IC) model for patients after a stroke.25 This IC 
model targeted seven modifiable risk factors including blood 
pressure, cholesterol, atrial fibrillation, body mass index (BMI), 
smoking, alcohol intake, and physical activity. The IC model 
included optimization of pharmacotherapy and patient 
education, with counseling specific towards stroke risk factor 
modification. Over the year of the study, patients in the IC 
group, compared to the control group, met their goals for 
Student Project PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                          2017, Vol. 8, No. 4, Article 5                        INNOVATIONS in pharmacy   5 
 
systolic blood pressure and BMI and showed greater 
improvement in disability. One limitation of the study was rates 
of recurrent stroke were not evaluated. 
 
Limitations and Challenges 
Limitations of this study and analysis of results include 
incomplete documentation of contraindications to 
medications, economic factors and patient access to 
medications, patients receiving additional treatment at outside 
facility, and sample size when compared to similar published 
studies. Even with these limitations, the adherence to 
evidence-based practice was staggeringly low for patients 
admitted with recurrent ischemic stroke. Theoretical 
challenges for secondary prevention include lack of 
prioritization and consistency of secondary prevention follow-
up and treatment by health care professionals.26,27 Gaps in 
education and health literacy also exist between patients and 
physicians, which may create a poor environment for 
addressing patient concerns and decrease adherence to 
medications.10 Finally, unlike previous studies, this study was 
conducted in a smaller community hospital, which may be more 
representative of “real-life” care experienced by patients in 
rural settings. Further studies would be necessary to identify 
the significance of disparities in guidelines versus care received 
in academic versus community hospital settings, as well as the 
reasons behind them. 
 
There is much room for improvement in risk factor 
management among secondary stroke patients. Studies 
acknowledge that patients with risk factors for stroke typically 
do not follow physicians’ suggestions regarding lifestyle 
modifications and adherence to medications for prevention.10 
Achieving a comprehensive patient education and medication 
management plan post-stroke would likely improve patients’ 
understanding of their disease state, the importance of 
secondary prevention, and how to manage their risk factors. 
These tasks could be completed by healthcare professionals 
such as pharmacists, who are increasingly available in hospital 
settings to assist in transitions of care, medication 
reconciliation, and patient education, and who are trained 
specifically to manage complex medication regimens and 
improve patient education on medication use. 
  
CONCLUSION 
Significant opportunities for improvement in secondary stroke 
prevention prior to hospital discharge exist in this setting of a 
community hospital. Secondary prevention of stroke through 
optimized pharmacotherapy is crucial in order to promote the 
best possible patient outcomes. Standardized care plans are 
one potential option to promote better adherence to practice 
guidelines for post-stroke patient management, in addition to 
discharge orders and increased patient counseling which are 
focused and inexpensive interventions that can improve 
adherence to secondary stroke prevention measures. Further 
research is needed to compare the difference in guideline-
driven care received by patients in community versus academic 
hospitals, and to identify effective solutions in both settings.     
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APPENDIX 
 
 
Table 1. Patient Demographics 
Patient Demographics 
Characteristic No. (%) 
Mean Age (yrs) 68 ± 11 
Gender  
Male 
Female 
57 (54%) 
48 (46%) 
Race  
White 
African American 
Hispanic 
87 (83%) 
17 (16%) 
1 (1%) 
Relevant disease states  
Chronic kidney disease/renal insufficiency 27 (26%) 
Atrial fibrillation 20 (19%) 
Atrial fibrillation + coronary artery disease 12 (11%) 
Documented allergies/intolerances to recommended medications (anaphylaxis, myopathy, drug-induced 
electrolyte imbalances, etc.) 
On admission  9 (9%) 
New onset intolerances at discharge  8 (8%) 
Total Strokes (n=105) 
Noncardioembolic Stroke 
Cardioembolic Stroke 
82 (78%) 
23 (22%) 
#Stroke for Patient  
Second 
Third 
Fourth 
88 (84%) 
11 (10%) 
6 (6%) 
Readmission for stroke within 30 days 4 (4%) 
 
 
Table 2. Appropriate Medication Use 
Appropriate Medication Use  
No. (%) No. (%)  
Noncardioembolic Cardioembolic 
Guideline-based; appropriate 7 (8%) 1 (4%) 
Not guideline-based; appropriate 16 (20%) 2 (9%) 
Not guideline-based; not appropriate 59 (72%) 20 (87%) 
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Table 3. Overall Breakdown of Medication Use 
 
Overall Breakdown of Medication Use 
  Patients Prescribed (%) Patients Prescribed (%) 
  Noncardioembolic Cardioembolic 
Diuretic  23 (28%) 7 (30%) 
Diuretic only 11 (13%) 1 (4%) 
Diuretic + ACEi 12 (15%) 6 (26%) 
ACE inhibitor (ACEi) 43 (52%) 15 (65%) 
High Intensity Statin 21 (26%) 4 (17%) 
Antiplatelet 78 (95%) 19 (83%) 
Oral Anticoagulant (OAC) ---- 22 (96%) 
 
 
 
Table 4. Medication Use within Each Outcome 
 
Medication Use Within Each Outcome 
  Patients Prescribed (%) Patients Prescribed (%) 
  Noncardioembolic Cardioembolic 
Guideline-based; appropriate 7 (9%) 1 (4%) 
Diuretic 7 1 
ACE inhibitor (ACEi) 5 1 
High Intensity Statin 6 1 
Antiplatelet 7 1 
Oral Anticoagulant (OAC) ---- 1 
Not guideline-based; appropriate 16 (20%) 2 (9%) 
Diuretic 4 0 
ACE inhibitor (ACEi) 10 2 
High Intensity Statin 7 0 
Antiplatelet 15 2 
Oral Anticoagulant (OAC) ---- 2 
Not guideline-based; 
not appropriate 59 (72%) 20 (87%) 
Diuretic 12 6 
ACE inhibitor (ACEi) 31 13 
High Intensity Statin 8 3 
Antiplatelet 57 16 
Oral Anticoagulant (OAC) ---- 19 
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Figure 1. Medication Use in Noncardioembolic Stroke 
 
 
 
 
 
Figure 2. Medication Use in Cardioembolic Stroke 
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